Anti-ROR1 Antibody Internalization for ADC Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-drug conjugates (ADCs) targeting ROR1 lack high specificity and efficacy, necessitating the development of antibodies with high affinity for ROR1 and the ability to internalize into cells, as well as ADCs with effective therapeutic effects.
Innovation Solution
The development of anti-ROR1 antibodies with high affinity and internalization capabilities, specifically designed to form effective antibody-drug conjugates (ADCs) that target and kill ROR1-expressing cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional ADCs are used to target ROR1, then they can deliver cytotoxic agents to tumor cells, but they lack high specificity and efficacy due to insufficient affinity and internalization capability
Solution Approach 1:
The patent applies parameter changes by modifying the antibody structure to achieve high affinity binding to ROR1. The developed anti-ROR1 antibodies exhibit significantly improved binding characteristics compared to conventional ADCs, enabling specific recognition and internalization into ROR1-expressing tumor cells while minimizing off-target effects
Solution Approach 2:
The patent implements preliminary action by designing antibodies with built-in internalization capabilities before ADC formation. The anti-ROR1 antibodies are engineered to actively internalize into cells upon binding, ensuring that the cytotoxic payload is delivered inside the tumor cell rather than remaining on the surface, thereby improving efficacy while reducing systemic toxicity
2Strength
If ADCs with high cytotoxic effects are developed, then tumor-killing capability is improved, but toxicity increases and high specificity is required
Solution Approach 1:
The patent applies local quality by concentrating the cytotoxic effect specifically at the tumor cell level through ROR1-specific targeting. The anti-ROR1 antibodies ensure that high-dose cytotoxic agents are delivered only to ROR1-expressing tumor cells, while healthy tissues without ROR1 expression remain unaffected, thereby achieving strong local tumor-killing effects with minimal systemic toxicity
Solution Approach 2:
The patent uses the anti-ROR1 antibody as an intermediary that mediates between the cytotoxic payload and the tumor cell. This intermediary provides the necessary specificity and internalization function, allowing potent cytotoxic agents to be safely delivered to and activated within tumor cells while protecting healthy tissues from exposure
3Measurement precision
If antibodies with high affinity for ROR1 are developed, then target recognition is improved, but the complexity of antibody development and characterization increases
Solution Approach 1:
The patent implements preliminary action by pre-engineering antibodies with optimized binding characteristics during the development phase. The anti-ROR1 antibodies are designed with predetermined high affinity for ROR1, reducing the need for extensive iterative optimization and characterization compared to conventional antibody development approaches
Data Source
AI summary
The present application relates to antibodies that specifically recognize ROR1, and preparation methods and uses thereof. The present application also relates to antibody-drug conjugates (ADCs) targeting ROR1 and compositions containing the molecule. In addition, the present invention also relates to the therapeutic and diagnostic uses of these antibodies, antibody fragments and antibody-drug conjugates.